Want to see TSE:GREY full AI Analyst Report?
GREY Stock Chart & Stats
C$0.39
>-C$0.01(-1.27%)
At close: 4:00 PM EDT
C$0.39
>-C$0.01(-1.27%)
Day’s Range― - ―
52-Week RangeC$0.34 - C$0.90
Previous CloseN/A
Volume4.50K
Average Volume (3M)13.80K
Market Cap
C$3.61M
Enterprise ValueC$3.70
Total Cash (Recent Filing)C$210.03K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta0.06
Next Earnings
Dec 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding8,923,237
10 Day Avg. Volume14,017
30 Day Avg. Volume13,803
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.77
Price to Sales (P/S)0.00
P/FCF Ratio-1.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.84
Revenue Forecast (FY)C$1.12M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free balance sheet materially lowers financial fixed charges and interest risk, improving resilience during prolonged development cycles. Over 2–6 months this supports the company's ability to prioritize product development or equity financing without near-term debt service constraints.
Narrowing Net LossesA clear, multi-year reduction in net losses signals improved cost control and operating discipline. Structurally, narrowing losses extend runway and raise the likelihood management can reach breakeven or scale with fewer capital injections, improving long-term survival odds.
Focus On Digital Mental & Neuro TherapeuticsSpecialization in software-based mental and neurological therapeutics aligns with durable secular demand for digital health solutions. Software therapeutics are scalable, potentially recurring, and can leverage regulatory pathways and payer adoption over time to build defensible revenue streams.
Bears Say
Zero Reported RevenueAbsence of revenue is a fundamental constraint: the business has not yet validated commercial adoption or unit economics. Without recurring sales, forecasting sustainable margins or cash generation is speculative, increasing execution and financing risk over the medium term.
Persistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flow means the company is burning cash to fund operations. Even with improvement, ongoing negative FCF reduces strategic optionality and forces management to prioritize runway extension, which can slow commercialization or R&D investments.
Reliance On External Funding Due To Cash BurnDependence on external capital creates structural dilution and timing risk; access to funding may be constrained if market conditions or investor appetite shift. Over several months this reliance can limit strategic choices and increase execution uncertainty for product commercialization.
Grey Matters Health News
GREY FAQ
What was Grey Matters Health’s price range in the past 12 months?
Grey Matters Health lowest stock price was C$0.34 and its highest was C$0.90 in the past 12 months.
What is Grey Matters Health’s market cap?
Grey Matters Health’s market cap is C$3.61M.
When is Grey Matters Health’s upcoming earnings report date?
Grey Matters Health’s upcoming earnings report date is Dec 18, 2026 which is in 128 days.
How were Grey Matters Health’s earnings last quarter?
Grey Matters Health released its earnings results on Jul 29, 2026. The company reported -C$0.13 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Grey Matters Health overvalued?
According to Wall Street analysts Grey Matters Health’s price is currently Overvalued.
Does Grey Matters Health pay dividends?
Grey Matters Health does not currently pay dividends.
What is Grey Matters Health’s EPS estimate?
Grey Matters Health’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Grey Matters Health have?
Grey Matters Health has 8,923,237 shares outstanding.
What happened to Grey Matters Health’s price movement after its last earnings report?
Grey Matters Health reported an EPS of -C$0.13 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.667%.
Which hedge fund is a major shareholder of Grey Matters Health?
Currently, no hedge funds are holding shares in TSE:GREY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Grey Matters Health
Grey Matters Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. Its pipeline includes repirinast for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine for the treatment of strokes and traumatic brain injuries. The company was formerly known as Algernon Health Inc. and changed its name to Grey Matters Health Inc. in April 2026. Algernon Health Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Technical Analysis
Appili Therapeutics Inc Class A
―
Rakovina Therapeutics Inc
―
Universal Ibogaine Inc
―
Mindbio Therapeutics Corp.
―
Neural Therapeutics Inc.
―